From the 1Institute of Social Medicine and Health Systems Research, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany
2University of Regensburg, Regensburg, Germany
3Dr. August Wolff GmbH & Co. KG Arzneimittel, Bielefeld, Germany
Received September 30, 2022; revised and accepted November 28, 2022.
Funding/support: Dr. August Wolff GmbH & Co. KG Arzneimittel, Bielefeld, Germany was sponsor of the clinical trials (VMP-03/2018 and VFCrC-01/2021).
Financial disclosure/conflicts of interest: M.G. has received consultancy fees from Effik. C.J.A. has received institutional funding and consultancy fees from Dr. Wolff GmbH, Bielefeld, Germany, and Bionorica, Neumarkt, Germany. He has received consultancy fees from Dr Wolff GmbH, Sanofi, Bionorica, and Effik for services related to patient-reported outcomes. A.H. and C.M. are employed by Dr. August Wolff GmbH & Co. KG Arzneimittel, Bielefeld, Germany.
Supplemental digital content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal’s Website (www.menopause.org).
Address correspondence to: Michaela Gabes, MSc, Leipziger Str. 44, 39120 Magdeburg, Germany. E-mail: [email protected]